<DOC>
	<DOCNO>NCT01719926</DOCNO>
	<brief_summary>Mesenchymal stem cell ( MSCs ) present circulation cancer patient , recruit stroma primary tumor metastasis . Recent preclinical research show response platinum-based chemotherapy , MSCs secrete two specific platinum-induced fatty acid ( PIFAs ) induce resistance broad spectrum chemotherapy . The secreted PIFAs fatty acid oxo-heptadecatetraenoic acid ( KHT ) omega-3 fatty acid hexadecatetraenoic acid ( 16:4 ) . These PIFAs produce via COX-1 pathway . COX inhibitor , include indomethacin . This phase 1 study explores safety combine indomethacin platinum contain chemotherapy .</brief_summary>
	<brief_title>Phase I Platinum Based Chemotherapy Plus Indomethacin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Subjects histological proven malignancy receive cisplatin combine gemcitabine 5FU/capecitabine . ( cisplatin dose range 6080 mg/m2 ) ( Arm I ) CAPOX ( oxaliplatin , capecitabine ) ( Arm II ) 21 day cycle . Age ≥ 18 year Platinumbased chemotherapy naïve least 6 month . Subjects least one evaluable lesion . WHO Performance Status 0 1 . Female participant nonchild bear potential either physiologic use adequate contraception , negative serum pregnancy test , refrain breast feeding . Written informed consent . Known suspected allergy hypersensitivity indomethacin agent give association trial , particular subject history severe hypersensitivity reaction antiemetic ( 5HT3 antagonist , metoclopramide corticosteroid ) acetylsalicylic acid prostaglandin synthetase inhibitor . Symptomatic brain meningeal tumor Subjects seizure disorder require medication ( corticosteroids antiepileptic ) . Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study : Uncontrolled high blood pressure , history labile hypertension , history poor compliance antihypertensive regimen Unstable angina pectoris Symptomatic congestive heart failure NYHA class ≥ 3 ( see appendix 13.6 ) Myocardial infarction ≤ 6 month prior randomization Serious uncontrolled cardiac arrhythmia Active peptic ulcer disease , gastritis , inflammatory bowel disease . History active gastrointestinal bleeding History cerebrovascular disease Bleeding diathesis Chronic renal disease define GFR ( MDRD ) &lt; 60 ml/min Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L ( &lt; 1500/mm3 ) Platelets ( PLT ) &lt; 100 x 109/L ( &lt; 100,000/mm3 ) Hemoglobin ( Hgb ) &lt; 6.0 mmol/l ( patient may transfuse achieve adequate Hb ) Partial thromboplastin time ( PTT ) &gt; 1,5 x ULN Serum bilirubin &gt; 1.5 ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &gt; 3.0 x ULN ( &gt; 5 x ULN liver metastasis present ) Patients unable unwilling comply protocol Chronic treatment corticosteroid agent ( nebulized corticosteroid allow ) Patients receive radiation therapy within 4 week start study Patients receive experimental agent le 4 week start study . Patients use Omega3/omega6 contain product , include fish oil product less 2 week start study . Chronic use NSAID 's and/or acetylsalicylic acid and/or prostaglandin synthetase inhibitor . Use anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Esophageal</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>PIFA</keyword>
</DOC>